Study guide

19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis

Key Takeaways Explain This Topic AI

PR3-ANCA (cytoplasmic) is typical of granulomatosis with polyangiitis; MPO-ANCA (perinuclear) is typical of microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis.

Organ-threatening ANCA-associated vasculitis is induced with corticosteroids plus either rituximab or cyclophosphamide, with plasma exchange reserved for selected severe renal or pulmonary disease.

Cryoglobulinaemic vasculitis is strongly associated with hepatitis C and causes palpable purpura, arthralgia, neuropathy and low C4.

Last updated: September 2026

4. Small Vessel Vasculitides: ANCA-Associated Vasculitides (AAV)

ANCA-associated vasculitides are systemic necrotizing vasculitides targeting small vessels (arterioles, capillaries, venules) characterized by pauci-immune necrotizing crescentic glomerulonephritis and circulating antineutrophil cytoplasmic antibodies (ANCA) : ANCA Patterns & Antigenic Specificities

  • |
  • +-----------------------------------+-----------------------------------+
  • | |
  • 1. Cytoplasmic ANCA (c-ANCA) 2. Perinuclear ANCA (p-ANCA)
  • Antigen: Proteinase 3 (PR3) - Antigen: Myeloperoxidase (MPO)
  • Granulomatosis with Polyangiitis (GPA / Wegener's) - Microscopic Polyangiitis (MPA) (80%)
  • (> 90% sensitivity & specificity) - Eosinophilic GPA (EGPA / Churg-Strauss) (40-50%)
  • Cavitating pulmonary nodules; saddle-nose - Pulmonary-renal syndrome; severe asthma/eosinophilia
  • Granulomatosis with Polyangiitis (GPA, formerly Wegener's Granulomatosis)

Systemic necrotizing granulomatous vasculitis with a classic clinical triad:

Upper Respiratory Tract (Ear, Nose & Throat - 90%): Severe, chronic, bloody, purulent rhinosinusitis, recurrent epistaxis, nasal mucosal crusting, chondritis with nasal septal perforation and destruction of the nasal bridge producing the pathognomonic saddle-nose deformity . Chronic otitis media, conductive/sensorineural hearing loss, and subglottic stenosis presenting with progressive dyspnoea and inspiratory stridor.

Lower Respiratory Tract (Pulmonary - 80%): Cough, haemoptysis, pleuritic chest pain. Chest radiography and CT reveal multiple bilateral cavitating pulmonary nodules , thick-walled cavitary lesions, and patchy ground-glass infiltrates representing diffuse alveolar haemorrhage .

Renal (Glomerulonephritis - 75–80%): Rapidly progressive crescentic glomerulonephritis; active nephritic sediment with dysmorphic RBCs and red cell casts, leading to acute renal failure.

Other Manifestations: Proptosis / retro-orbital pseudotumour, scleritis, mononeuritis multiplex, and pyoderma gangrenosum-like cutaneous ulcers.

Diagnostic Serology: c-ANCA (cytoplasmic staining pattern on indirect immunofluorescence) directed specifically against Proteinase 3 (PR3-ANCA) ; positive in > 90% of active systemic GPA.

Histopathology: Triad of: (1) Necrotizing vasculitis of small arteries/veins; (2) Geographic necrosis surrounded by palisading histiocytes; and (3) Poorly formed granulomas with multinucleated giant cells.

Microscopic Polyangiitis (MPA)

Systemic necrotizing small-vessel vasculitis manifesting as a severe pulmonary-renal syndrome :

Clinical Presentation: Rapidly progressive necrotizing crescentic glomerulonephritis accompanied by pulmonary capillaritis presenting as life-threatening diffuse alveolar haemorrhage (haemoptysis, acute drop in haemoglobin, bilateral alveolar consolidation, and elevated carbon monoxide transfer coefficient [KCO] due to intra-alveolar RBC uptake of CO).

Vital Contrasts with GPA:

  • NO granulomatous inflammation on biopsy;
  • NO upper respiratory tract (ENT) destruction (no saddle-nose, no sinus crusting, no subglottic stenosis); and

NO cavitating lung nodules on imaging.

Diagnostic Serology: p-ANCA (perinuclear staining pattern) directed specifically against Myeloperoxidase (MPO-ANCA) ; positive in > 75–85% of MPA patients.

Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss)

Eosinophil-rich necrotizing granulomatous vasculitis characterized by three distinct clinical phases:

Prodromal / Allergic Phase: Severe, late-onset, adult-onset refractory asthma , allergic rhinitis, and nasal polyposis, typically persisting for years.

Eosinophilic Infiltrative Phase: Marked peripheral blood eosinophilia (> 10% of total white cells, or absolute eosinophil count > 1.5 × 10⁹/L) and tissue eosinophilic infiltration (eosinophilic gastroenteritis, eosinophilic pneumonia with migratory, non-cavitating pulmonary infiltrates).

Systemic Vasculitic Phase: Systemic small-vessel vasculitis manifesting as:

Mononeuritis Multiplex: Present in > 70% of patients; the most frequent vasculitic feature.

Cardiovascular Disease: Eosinophilic myocarditis , endomyocardial fibrosis, pericarditis, and coronary arteritis; cardiac involvement represents the primary cause of mortality in EGPA .

Renal: Pauci-immune necrotizing crescentic GN (typically milder and less frequent than in GPA or MPA).

Diagnostic Serology: p-ANCA / MPO-ANCA is positive in only 40–50% of EGPA patients. Clinical dichotomy: ANCA-positive patients predominantly suffer from glomerulonephritis, mononeuritis multiplex, and purpura; ANCA-negative patients predominantly suffer from cardiomyopathy, pericarditis, and severe lung infiltration.

Management of ANCA-Associated Vasculitides

Remission Induction (Organ- or Life-Threatening Disease):

High-dose intravenous pulsed methylprednisolone (500–1,000 mg IV daily for 3 days) followed by tapering oral prednisolone;

PLUS either Rituximab (375 mg/m² weekly for 4 doses or 1,000 mg IV every 2 weeks for 2 doses) OR intravenous Cyclophosphamide (15 mg/kg IV every 2–3 weeks for 3–6 months).

Rituximab is now the preferred first-line agent, especially in patients with relapsing disease, childbearing potential (preserves ovarian/testicular reserve), and PR3-ANCA positive GPA.

Avacopan: Oral selective complement C5a receptor (C5aR1) antagonist , approved as an adjunctive therapy to reduce or eliminate high-dose glucocorticoid exposure during induction.

Mandatory Prophylaxis: All patients receiving induction immunosuppression for AAV must receive co-trimoxazole (e.g. 480 mg daily or 960 mg three times weekly) as mandatory antimicrobial chemoprophylaxis against Pneumocystis jirovecii pneumonia (PJP) .

Remission Maintenance: Transition to maintenance therapy after achieving remission at 3–6 months: maintenance rituximab infusions every 6 months, or oral azathioprine (2 mg/kg/day) or oral methotrexate , continued for at least 24–48 months.

  • 5. Immune Complex Small Vessel Vasculitides
  • IgA Vasculitis (Henoch-Schönlein Purpura - HSP)

Systemic small-vessel leukocytoclastic vasculitis characterized by tissue deposition of IgA1-dominant immune complexes .

Epidemiology: Most common vasculitis of childhood (peak age 4–7 years), but can occur in adults where it carries a much higher risk of progressive, chronic renal disease.

Classic Clinical Tetrad:

Palpable Purpura: Non-thrombocytopenic, symmetrical, raised purpuric lesions and petechiae distributed gravitationally over dependent areas—predominantly the buttocks and lower extremities (spares trunk and face).

Arthralgia / Non-Deforming Arthritis: Transient oligoarthritis affecting knees and ankles without permanent erosion.

Gastrointestinal Symptoms: Colicky, cramping abdominal pain, nausea, vomiting, gastrointestinal bleeding, and bowel ischemia. In young children, bowel wall edema can trigger ileo-ileal or ileocolic intussusception .

Renal Disease (IgA Glomerulonephritis): Microscopic haematuria, sub-nephrotic proteinuria, and nephritic syndrome. Renal histology is indistinguishable from primary IgA nephropathy (Berger's disease).

Diagnostic Investigation: Coagulation profile and platelet count are COMPLETELY NORMAL (distinguishing it from ITP, TTP, or DIC). Skin punch biopsy demonstrates leukocytoclastic vasculitis with diagnostic, pathognomonic perivascular IgA and C3 deposition on direct immunofluorescence.

Management: Primarily supportive (analgesia, hydration). Systemic corticosteroids are indicated for severe disabling abdominal pain or progressive glomerulonephritis, but do not prevent renal progression.

Cryoglobulinaemic Vasculitis

Systemic vasculitis driven by cryoglobulins —immunoglobulins that reversibly precipitate at cold temperatures (< 37 °C) and redissolve upon warming.

Classification (Brouet Criteria):

Type I (Monoclonal): Monoclonal IgM or IgG. Associated with lymphoproliferative disorders (multiple myeloma, Waldenström's macroglobulinaemia); causes hyperviscosity and digital necrosis.

Type II (Mixed): Monoclonal IgM with rheumatoid factor activity directed against polyclonal IgG.

Type III (Polyclonal): Polyclonal IgM with rheumatoid factor activity directed against polyclonal IgG.

Strong Association with Hepatitis C Virus (HCV): > 80–90% of mixed cryoglobulinaemia (Types II and III) is secondary to chronic Hepatitis C virus infection.

Clinical Features: Meltzer's Triad —palpable purpura, severe arthralgias, and profound fatigue/asthenia. Also causes mononeuritis multiplex, digital ischemia, and type I membranoproliferative glomerulonephritis (MPGN).

Serology: Detectable serum cryoglobulins, positive Rheumatoid Factor (RF > 90%), detectable HCV RNA, and characteristically profound depression of serum C4 (C4 is typically undetectable or near-zero, while C3 is normal or mildly depressed).

Management: Direct-acting antiviral (DAA) therapy to eliminate HCV; rituximab and plasma exchange for severe vasculitic flares.

6. Comparative Synthesis: ANCA-Associated Vasculitides

Feature Granulomatosis with Polyangiitis (GPA) Microscopic Polyangiitis (MPA) Eosinophilic GPA (EGPA / Churg-Strauss)

Primary Pathology Necrotizing granulomatous small-vessel vasculitis Necrotizing non-granulomatous small-vessel vasculitis Eosinophil-rich necrotizing granulomatous vasculitis

Granulomas Present (geographic necrosis, giant cells) Strictly Absent Present (eosinophilic necrotizing granulomas)

Dominant ANCA c-ANCA / Anti-PR3 (> 90%) p-ANCA / Anti-MPO (> 80%) p-ANCA / Anti-MPO (40–50%)

Upper Respiratory (ENT) Severe destruction : sinusitis, saddle-nose, subglottic stenosis Absent (no ENT involvement) Allergic rhinitis, nasal polyposis (non-destructive)

Lower Respiratory Cavitating nodules , alveolar haemorrhage Alveolar haemorrhage ; no cavitating nodules Late-onset asthma , transient pulmonary infiltrates

Renal Disease Rapidly progressive crescentic GN (pauci-immune) Rapidly progressive crescentic GN (severe) Crescentic GN (milder; in ~25–30%)

  • Blood Eosinophilia Absent Absent Marked peripheral eosinophilia (> 10% / > 1.5 x 10⁹/L)
  • Cardiovascular Rare Rare Eosinophilic myocarditis (leading cause of death)

First-Line Induction High-dose steroids + Rituximab or Cyclophosphamide High-dose steroids + Rituximab or Cyclophosphamide High-dose steroids + Cyclophosphamide (if FFS >= 1) / Mepolizumab

PJP Prophylaxis Mandatory Co-trimoxazole Mandatory Co-trimoxazole Mandatory Co-trimoxazole